Table 3 |.
Summary of trials involving DNMT inhibitors
| Agents | Trial phase (n) | Lymphoma subtype | Outcomes | Common grade ≥3 adverse events (% of patients) | Year | Refs or ClinicalTrials.gov identifier |
|---|---|---|---|---|---|---|
| Azacitidine + R-CHOP | I (33) | DLBCL, FL (grade 3b) and tFL | ORR 97% and CRR 85% | In 64% in total, including neutropenia (58); febrile neutropenia (21) | 2017 | 76 |
| Azacitidine + romidepsin | II (30) | HL, NHL and TCL | NHL: ORR 28% and CRR 16%; PTCL: ORR 83% and CRR 50% | NR | 2017 | 79 |
| Azacitidine+vorinostat + HDT-ASCT | I (60) | DLBCL, HL and TCL | DLBCL: EFS 65% and OS 77%; HL: EFS 76% and OS 95%; TCL: EFS 88% and OS 88% (all at a median follow-up duration of 15 months) | Neutropenic fever (100); mucositis (32); elevated transaminase levels (25) | 2016 | 78 |
| Azacitidine + R-CHOP | I (12) | DLBCL | CRR 92% | Neutropenia (100); neutropenic fever (33) | 2013 | 64 |
| Azacitidine | II (9) | CLL | ORR 0% | NR | 2013 | 73 |
| Azacitidine + R-CV | I (10) | DLBCL, FL,HL, SLL and CTCL | ORR 20%, CRR 10% and CBR40% | Neutropenia (50); thrombocytopenia (40); anaemia (20) | 2011 | 77 |
| Decitabine | I (20) | CLL and NHL | ORR 0% | Thrombocytopenia (55); neutropenia (45); febrile neutropenia (35) | 2010 | 74 |
| Decitabine + R-CHOP | I/II | DLBCL | Study ongoing | - | 2016 | NCT02951728 |
| Azacitidine + avelumab + utomilumab | Ib | DLBCL | Study ongoing | - | 2016 | NCT02951156 |
CBR, clinical benefit rate; CLL, chronic lymphocytic leukaemia; CRR, complete response rate; CTCL, cutaneous T cell lymphoma; DLBCL, diffuse large B cell lymphoma; DNMT, DNA methyltransferase; EFS, event-free survival; FL, follicular lymphoma; HDT-ASCT, high-dose therapy-autologous stem cell transplantation; HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma; NR, not reported; ORR, overall response rate; OS, overall survival; PTCL, peripheral T cell lymphoma; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; R-CV, rituximab, cyclophosphamide and vincristine; SLL, small lymphocytic leukaemia; TCL, T cell lymphoma; tFL, transformed follicular lymphoma.